BDX Stock Overview
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Becton, Dickinson and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$230.48 |
| 52 Week High | US$287.32 |
| 52 Week Low | US$229.40 |
| Beta | 0.46 |
| 1 Month Change | -4.71% |
| 3 Month Change | -2.61% |
| 1 Year Change | -12.46% |
| 3 Year Change | -8.33% |
| 5 Year Change | -2.62% |
| Change since IPO | 8,889.85% |
Recent News & Updates
Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)
Mar 23
Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)
Feb 29Recent updates
Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)
Mar 23Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)
Feb 29Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings
Feb 08Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 03These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well
Feb 01Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play
Jan 22Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year
Nov 30Becton, Dickinson And Company: Strong Q4 But Clouded By 75bps Growth Headwind From China In FY24
Nov 13Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's
Nov 12Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price
Nov 06With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case
Oct 05Becton, Dickinson Stock Is A Hold, Here's Why
Oct 04Becton, Dickinson: Ahead Of Schedule, Undervalued, And With Some Positive Drivers
Aug 30We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt
Aug 13Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Jul 28Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching
Jun 22Becton, Dickinson and Company: Still Not Very Healthy
Jun 20Becton, Dickinson: Business Should Beat H2 2023 Expectations
Jun 08These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well
Apr 22Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?
Mar 20Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Mar 05Becton, Dickinson HPV test Onclarity gets FDA nod for expanded use
Feb 21Becton, Dickinson wins FDA nod for flu, COVID, RSV combo test
Feb 08Becton, Dickinson Q1 2023 Earnings Preview
Feb 01Becton, Dickinson declares $0.91 dividend
Jan 24We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt
Jan 09CerTest/Becton, Dickinson's test for monkeypox gets FDA emergency use nod
Jan 09Becton, Dickinson: A Quality Defensive Pick For 2023
Dec 20Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Dec 01Becton Dickinson (NYSE:BDX) Is Increasing Its Dividend To $0.91
Nov 13Becton, Dickinson Q4 2022 Earnings Preview
Nov 09Becton, Dickinson, Biocorp team up for traceability of injectable drugs
Oct 18Becton, Dickinson: Buy In Now While You Can
Oct 12Does Becton Dickinson (NYSE:BDX) Have A Healthy Balance Sheet?
Oct 05BD, Certest Biotec launch monkeypox test
Sep 26Becton, Dickinson launches next-gen prefillable vaccine syringe BD Effivax
Sep 13Shareholder Returns
| BDX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.1% | 1.6% | 1.0% |
| 1Y | -12.5% | -1.4% | 21.9% |
Return vs Industry: BDX underperformed the US Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: BDX underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| BDX volatility | |
|---|---|
| BDX Average Weekly Movement | 2.5% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BDX has not had significant price volatility in the past 3 months.
Volatility Over Time: BDX's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 73,000 | Tom Polen | www.bd.com |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Becton, Dickinson and Company Fundamentals Summary
| BDX fundamental statistics | |
|---|---|
| Market cap | US$66.59b |
| Earnings (TTM) | US$1.27b |
| Revenue (TTM) | US$19.49b |
52.6x
P/E Ratio3.4x
P/S RatioIs BDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDX income statement (TTM) | |
|---|---|
| Revenue | US$19.49b |
| Cost of Revenue | US$10.78b |
| Gross Profit | US$8.72b |
| Other Expenses | US$7.45b |
| Earnings | US$1.27b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 4.38 |
| Gross Margin | 44.72% |
| Net Profit Margin | 6.49% |
| Debt/Equity Ratio | 63.6% |
How did BDX perform over the long term?
See historical performance and comparison